PF-07817883 + midazolam

A combination of **PF-07817883** (ibuzatrelvir), an investigational oral SARS-CoV-2 main protease inhibitor developed by Pfizer for COVID-19, and **midazolam**, a well-characterized benzodiazepine commonly used as a probe substrate for cytochrome P450 3A (CYP3A) enzyme activity in drug-drug interaction studies. PF-07817883 exhibits antiviral activity by inhibiting viral replication through reversible covalent binding to the active site of the SARS-CoV-2 3CL (main) protease. Midazolam is typically included in such combination pharmacokinetic studies to assess whether the investigational drug affects CYP3A-mediated metabolism, which is a common route for drug interactions. This combination is used in clinical research settings to evaluate the pharmacokinetic and drug-drug interaction profile of PF-07817883 in healthy volunteers, rather than as a therapeutic regimen.[1][2][3][5]

Other names

ibuzatrelvir + midazolam